Effects of Phosphate Binding With Sevelamer in Stage 3 Chronic Kidney Disease
Kidney FailureChronic1 moreThe purpose of this study is to determine whether lowering phosphate in patients with early chronic kidney disease with the phosphate binder sevelamer has beneficial effects on cardiovascular structure and function.
A Study To Investigate The Effects Of End Stage Renal Disease And Hemodialysis On The Pharmacokinetics...
Restless Legs SyndromeThis study will investigate the effects of severe renal impairment and hemodialysis on the characteristics of the drug, ropinirole.
Spironolactone and Prevention of Peritoneal Fibrosis in Peritoneal Dialysis
End Stage Renal DiseaseThis is a double blind randomized controlled study to evaluate the effect of aldactone on peritoneal fibrosis on incident peritoneal dialysis patients. The study would include a total of 40 incident peritoneal dialysis patients. Peritoneal biopsy would be made at randomization and 6 months after the intervention to evaluate the effect of renin angiotensin blockade on peritoneal fibrosis.
Evaluating Aranesp® for the Treatment of Anemia in African-American Subjects With Chronic Renal...
Chronic Renal FailureAnemiaThis study is designed to evaluate the hemoglobin response to Aranesp® (darbepoetin alfa) in black subjects (African-Americans) with chronic renal failure (CRF) receiving hemodialysis and to examine the safety profile.
The Fish and Fruit Study: Trial of Fish and Fruit to Improve Survival of Aboriginal People With...
Cardiovascular DiseasesCardiovascular disease is the main cause of death in patients on dialysis for end stage renal disease. Omega-3 fatty acids and antioxidants have been shown to be protective in the general population. A diet of fish and fruit, which will provide the fatty acids and the antioxidants is being tried in dialysis patients to assess the effect on cardiovascular disease in this high risk group.
Safety in Immunomodulatory Functions of Alemtuzumab (Campath) in Pediatric Kidney Transplantation...
Kidney FailureChronic2 moreThe purpose of this study is to evaluate the safety of alemtuzumab after kidney transplantation as part of a multitherapy regimen to prevent kidney graft loss and death and to avoid steroids and chronic use of calcineurin inhibitors in pediatric renal transplant recipients 1 to 20 years of age.
Induction Therapy Study in Live Donor Kidney Transplant Recipients With a Positive Crossmatch
Kidney FailureChronicThe purpose of this study is to determine whether the anti-T cell antibody, Thymoglobulin is a more effective induction medication than the anti-IL-2R inhibitor daclizumab, in kidney transplant recipients who have a positive crossmatch with their live donor.
Chlorhexidine Gluconate-gel Dressing for Exit Site Infection in Peritoneal Dialysis
Peritoneal Dialysis Catheter Exit Site InfectionEnd Stage Renal Disease on Dialysis1 moreExit site infection (ESI) is one of the major predisposing factors to peritoneal dialysis (PD) related peritonitis. Chlorhexidine Gluconate (CHG) has been widely used for cutaneous disinfection for half a century. TegadermTM CHG is a water-proof dressing with gel pads that provide 2% CHG to the skin surface and effectively prevents catheter-related infections for intravascular catheters. However, its use has not been accessed in patients with PD catheters. We aim to evaluate the effectiveness of TegadermTM CHG dressing in preventing ESI in PD patients.
A Novel Role of Alpha Lipoic Acid in Comparison With Selenium in Mitochondrial Resuscitation and...
Antioxidative StressEnd Stage Renal Disease on DialysisAn Open labeled, Paralled, Randomized, Prospective, study was conducted on 60 patients who were randomized into 3 groups, 22, 20 and 18 patients in Control, Selenium and, Thiotacid groups respectively. Serum levels of ROS, CoQ10, and miRNA-126 were assessed at base line and after three months for all patients.
A Study of Safety, PK, & PD of ISIS 416858 Administered Subcutaneously to Patients With End-Stage...
End-stage Renal Disease (ESRD)Evaluation of safety, tolerability, PK and PD of ISIS 416858 in patients with end-stage renal disease (ESRD) receiving chronic hemodialysis.